Tibra Equities Europe’s Alexion Pharmaceuticals ALXN Stock Holding History

Tibra Equities Europe’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-204,456	Closed	-$37.6M	–	265
2021 Q2	$37.6M	Sell	204,456 -36,150	-15%	-$6.21M	11.6%	1
2021 Q1	$36.8M	Buy	240,606 +97,249	+68%	+$15M	11.25%	1
2020 Q4	$22.4M	Buy	143,357 +128,057	+837%	+$16.5M	2.29%	12
2020 Q3	$1.75M	Buy	+15,300	New	+$1.65M	0.37%	43
2020 Q1	–	Sell	-12,100	Closed	-$1.31M	–	172
2019 Q4	$1.31M	Buy	+12,100	New	+$1.29M	0.18%	83

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tibra Equities Europe's ALXN Position: Q3 2021 in Review

Tibra Equities Europe sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 204,456 shares — an estimated $37.6M sold.

Tibra Equities Europe first reported a position in ALXN in Q4 2019 and held it in 5 quarters. The position peaked at $37.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Tibra Equities Europe reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Tibra Equities Europe sold 204,456 Alexion Pharmaceuticals shares in Q3 2021, an estimated $37.6M.
Tibra Equities Europe first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Tibra Equities Europe's Alexion Pharmaceuticals position peaked at $37.6M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.